KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non-Current Liabilities: 2009-2024

Historic Other Non-Current Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 12 years, with Dec 2024 value amounting to $393.1 million.

  • Alnylam Pharmaceuticals' Other Non-Current Liabilities rose 23.00% to $439.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $439.7 million, marking a year-over-year increase of 23.00%. This contributed to the annual value of $393.1 million for FY2024, which is 27.46% up from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Other Non-Current Liabilities is $393.1 million, which was up 27.46% from $308.4 million recorded in FY2023.
  • Alnylam Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $393.1 million for FY2024, and its period low was $37.9 million during FY2020.
  • In the last 3 years, Alnylam Pharmaceuticals' Other Non-Current Liabilities had a median value of $308.4 million in 2023 and averaged $304.7 million.
  • Data for Alnylam Pharmaceuticals' Other Non-Current Liabilities shows a peak YoY skyrocketed of 306.30% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Other Non-Current Liabilities stood at $37.9 million in 2020, then spiked by 161.06% to $99.0 million in 2021, then surged by 114.81% to $212.6 million in 2022, then spiked by 45.09% to $308.4 million in 2023, then climbed by 27.46% to $393.1 million in 2024.